End-of-day quote
INDONESIA S.E.
03:30:00 17/05/2024 am IST
|
5-day change
|
1st Jan Change
|
2,060
IDR
|
-0.96%
|
|
+3.52%
|
+12.26%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
62,55,000
|
62,77,500
|
63,00,000
|
67,64,796
|
63,58,909
|
82,75,601
|
Enterprise Value (EV)
1 |
48,16,403
|
45,40,048
|
43,35,777
|
49,18,675
|
42,22,487
|
55,22,412
|
P/E ratio
|
12.2
x
|
11.3
x
|
8
x
|
8.2
x
|
6.35
x
|
7.03
x
|
Yield
|
2.88%
|
3.58%
|
4.29%
|
4.67%
|
8.87%
|
-
|
Capitalization / Revenue
|
0.62
x
|
0.57
x
|
0.57
x
|
0.6
x
|
0.52
x
|
0.63
x
|
EV / Revenue
|
0.48
x
|
0.41
x
|
0.4
x
|
0.44
x
|
0.34
x
|
0.42
x
|
EV / EBITDA
|
5.31
x
|
4.46
x
|
3.33
x
|
3.79
x
|
4.52
x
|
4.09
x
|
EV / FCF
|
-43.2
x
|
10.3
x
|
11.8
x
|
42.2
x
|
324
x
|
7.43
x
|
FCF Yield
|
-2.32%
|
9.71%
|
8.48%
|
2.37%
|
0.31%
|
13.5%
|
Price to Book
|
1.22
x
|
1.14
x
|
1.04
x
|
1.04
x
|
0.88
x
|
1.08
x
|
Nbr of stocks (in thousands)
|
45,00,000
|
45,00,000
|
45,00,000
|
45,09,864
|
45,09,864
|
45,09,864
|
Reference price
2 |
1,390
|
1,395
|
1,400
|
1,500
|
1,410
|
1,835
|
Announcement Date
|
29/03/19
|
01/04/20
|
31/03/21
|
31/03/22
|
24/03/23
|
28/03/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
1,00,88,119
|
1,09,93,842
|
1,09,68,402
|
1,12,34,443
|
1,22,54,369
|
1,31,19,785
|
EBITDA
1 |
9,07,580
|
10,17,689
|
13,01,141
|
12,97,800
|
9,33,588
|
13,50,964
|
EBIT
1 |
7,02,576
|
7,97,080
|
10,75,647
|
11,04,347
|
7,28,658
|
10,79,831
|
Operating Margin
|
6.96%
|
7.25%
|
9.81%
|
9.83%
|
5.95%
|
8.23%
|
Earnings before Tax (EBT)
1 |
7,27,700
|
7,96,221
|
10,64,449
|
10,98,370
|
13,29,823
|
16,03,164
|
Net income
1 |
5,12,029
|
5,54,263
|
7,87,803
|
8,23,768
|
10,01,628
|
11,77,432
|
Net margin
|
5.08%
|
5.04%
|
7.18%
|
7.33%
|
8.17%
|
8.97%
|
EPS
2 |
113.8
|
123.2
|
175.1
|
183.0
|
222.0
|
261.0
|
Free Cash Flow
1 |
-1,11,501
|
4,40,624
|
3,67,844
|
1,16,568
|
13,021
|
7,43,613
|
FCF margin
|
-1.11%
|
4.01%
|
3.35%
|
1.04%
|
0.11%
|
5.67%
|
FCF Conversion (EBITDA)
|
-
|
43.3%
|
28.27%
|
8.98%
|
1.39%
|
55.04%
|
FCF Conversion (Net income)
|
-
|
79.5%
|
46.69%
|
14.15%
|
1.3%
|
63.16%
|
Dividend per Share
2 |
40.00
|
50.00
|
60.00
|
70.00
|
125.0
|
-
|
Announcement Date
|
29/03/19
|
01/04/20
|
31/03/21
|
31/03/22
|
24/03/23
|
28/03/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
14,38,597
|
17,37,452
|
19,64,223
|
18,46,122
|
21,36,422
|
27,53,189
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-1,11,501
|
4,40,624
|
3,67,844
|
1,16,568
|
13,021
|
7,43,613
|
ROE (net income / shareholders' equity)
|
10.3%
|
10.6%
|
13.7%
|
13.2%
|
14.4%
|
16%
|
ROA (Net income/ Total Assets)
|
5.74%
|
6.13%
|
7.69%
|
7.36%
|
4.34%
|
5.96%
|
Assets
1 |
89,23,315
|
90,35,767
|
1,02,40,386
|
1,11,88,395
|
2,30,64,631
|
1,97,53,246
|
Book Value Per Share
2 |
1,142
|
1,219
|
1,346
|
1,448
|
1,600
|
1,707
|
Cash Flow per Share
2 |
423.0
|
501.0
|
588.0
|
596.0
|
773.0
|
819.0
|
Capex
1 |
4,66,219
|
3,28,688
|
4,47,837
|
3,85,870
|
5,92,167
|
3,26,651
|
Capex / Sales
|
4.62%
|
2.99%
|
4.08%
|
3.43%
|
4.83%
|
2.49%
|
Announcement Date
|
29/03/19
|
01/04/20
|
31/03/21
|
31/03/22
|
24/03/23
|
28/03/24
|
|
1st Jan change
|
Capi.
|
---|
| +12.26% | 582M | | +32.09% | 693B | | +29.39% | 584B | | -1.34% | 372B | | +20.34% | 332B | | +7.39% | 294B | | +14.25% | 239B | | -3.03% | 211B | | +10.02% | 210B | | +8.49% | 168B |
Other Pharmaceuticals
|